C
Cardiol Therapeutics Inc. (CRDL)
NCM – Real Time Price. Currency in USD
1.35
+0.01 (1.12%)
At close: May 12, 2026, 4:00 PM EDT
1.33
-0.02 (-1.48%)
After-hours: May 12, 2026, 7:54 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.35
+0.01 (1.12%)
At close: May 12, 2026, 4:00 PM EDT
1.33
-0.02 (-1.48%)
After-hours: May 12, 2026, 7:54 PM EDT
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
| Name | Position |
|---|---|
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer and Head of Research & Development |
| Mr. Bernard Lim B.Sc. | Chief Operating Officer |
| Mr. Christopher J. Waddick C.A., C.M.A., CPA, MBA | CFO, Corporate Secretary & Director |
| Mr. David G. Elsley MBA | President, CEO & Director |
| Mr. John A. Geddes BSCPT, MBA | Vice President of Corporate Development |
| Trevor Burns | Investor Relations |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 6-K | cardiol6k.htm |
| 2026-04-28 | 6-K | cardiol6k.htm |
| 2026-04-14 | 6-K | form6k.htm |
| 2026-04-10 | 6-K | tm2611243d1_6k.htm |
| 2026-04-01 | 6-K | form6k.htm |
| 2026-03-31 | 40-F | crdl-20251231x40f.htm |
| 2026-02-25 | 6-K | form6k.htm |
| 2026-02-10 | 6-K | form6k.htm |
| 2026-02-02 | 6-K | tm264808d1_6k.htm |
| 2026-01-26 | 6-K | form6k.htm |